Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.

@article{Knobler1993SystemicRH,
  title={Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.},
  author={Robert Knobler and Jeffrey I. Greenstein and Kenneth P. Johnson and Fred D. Lublin and Hillel S. Panitch and Kevin C Conway and S V Grant-Gorsen and John Muldoon and Stephen G. Marcus and J C Wallenberg},
  journal={Journal of interferon research},
  year={1993},
  volume={13 5},
  pages={333-40}
}
A pilot study was undertaken to test the safety and establish the side effect profile of recombinant human interferon-beta 1b (Betaseron, Berlex Laboratories, Richmond, CA), in patients with relapsing-remitting multiple sclerosis (RRMS). During the initial dose finding period (24 weeks), five groups of 6 patients each were treated by subcutaneous injection three times each week with either 0.8, 4, 8, or 16 million units (mU) of Betaseron or placebo (WHO Standard). Although some side effects… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Interferon- β Therapy in Multiple Sclerosis

Drugs • 2012
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…